Status:
WITHDRAWN
A Study of ZD1839 Effects on Cell Proliferation in Breast Cancer
Lead Sponsor:
AstraZeneca
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
This is a Phase II, randomised, double-blind, placebo-controlled study. Subjects with histologically-confirmed oestrogen receptor negative (ER-), progesterone receptor negative (PgR-) primary breast c...
Eligibility Criteria
Inclusion
- Histologically-confirmed ER- and PgR- primary breast cancer
- Stage T .5 cm, N0-1, M0
- No previous treatment for breast cancer
Exclusion
- ALT or AST greater than 2.5 times the ULRR
- Metastatic disease
Key Trial Info
Start Date :
February 1 2004
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00252811
Start Date
February 1 2004
Last Update
January 28 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Milan, Italy